ReviewOncoTargets and therapy2018

A comparison of fulvestrant plus a targeted agent with fulvestrant alone in hormone receptor-positive advanced breast cancer that progressed on prior endocrine therapy: a meta-analysis.

Liang Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.